Institute for Translational Medicine and Therapeutics
The Institute for Translational Medicine and Therapeutics (ITMAT) was formally launched earlier this year under the direction of Dr. Garret A. FitzGerald. We have already made some progress which includes the establishment of internal and external advisory boards and both developed and have taken ownership of some core activities related to translational research. However, much more is to come, especially with the commencement of the new academic term.
ITMAT is currently offering membership to our newly founded Institute. The benefits of becoming a member of ITMAT are: (i) inclusion in the community of translational researchers at Penn, readily identifiable from within or outside Penn via membership of ITMAT—we anticipate that our website will become a particularly useful portal in this regard; (ii) immediate notification of new ITMAT initiatives—amongst those immediately on the horizon are a new seminar series, workshops and a launch meeting April 14 and 15, 2006; and (iii) eligibility for educational and research support grants provided via ITMAT. Additionally, ITMAT will support an increasing number of core services which will be provided to members at cost.
All members of ITMAT define themselves as involved primarily in Translational Research, defined as lying between proof of concept in cells or model systems and the conclusion of Phase II in humans.
If you meet this criterion and would like to become a member, please submit the following documents electronically to Esther Stuart at firstname.lastname@example.org.
• Brief note of request which includes your field of science and consequent relevance to ITMAT.
• NIH Biosketch and other support page.
• URL for your specific website.
• Inclusion of ITMAT in your listed affiliations on published work.
Additionally, ITMAT plans to support translational research through a Transdisciplinary Awards Program In Translational Medicine And Therapeutics (TAPITMAT). Initially, we shall consider funding four to six proposals in the region of $100,000-$150,000. These proposals require at least two co-principal investigators, ideally from different disciplines within the University of Pennsylvania, at least one of whom has a primary appointment in the School of Medicine. The proposals must center on the translational space—from proof of concept in cells or model systems through to completion of dose selection in Phase II in humans. Programs that plan to progress within that space and which deploy technologies and approaches conventionally segregated from each other within the traditional boundaries of academic medicine will be especially favored. The proposals are due by December 1, 2005.
For more information, please visit our website at www.itmat.upenn.edu.
–Lorri Schieri, Director, Fiscal and Administrative Operations,
Department of Pharmacology
Almanac, Vol. 52, No. 6, October 4, 2005